Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease

Molecular Neurodegeneration

Xiaoqi Wang¹  Yu Sun¹  Ying Han²  Frank Jessen³  Li Su⁴  Yue Xing⁵  Weijie Huang⁶  Ni Shu⁶ 

[1] Department of Neurology, Xuanwu Hospital of Capital Medical University, 100053, Beijing, China;Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China;Department of Neurology, Xuanwu Hospital of Capital Medical University, 100053, Beijing, China;Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China;National Clinical Research Center for Geriatric Disorders, Beijing, China;Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, 50937, Cologne, Germany;German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany;Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany;Department of Psychiatry, University of Cambridge, Cambridge, UK;Sino-Britain Centre for Cognition and Ageing Research, Southwest University, Chongqing, China;Radiological Sciences, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK;State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, 100875, Beijing, China;Center for Collaboration and Innovation in Brain and Learning Sciences, Beijing Normal University, Beijing, China;Beijing Key Laboratory of Brain Imaging and Connectomics, Beijing Normal University, Beijing, China;

关键词: subjective cognitive decline;    Alzheimer’s disease;    neuroimaging;    multimodal MRI;    PET;   

DOI  :  10.1186/s13024-020-00395-3

来源: Springer

【 摘 要 】

Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer’s disease (AD) continuum. Investigating populations with SCD is important for understanding the early pathological mechanisms of AD and identifying SCD-related biomarkers, which are critical for the early detection of AD. With the advent of advanced neuroimaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), accumulating evidence has revealed structural and functional brain alterations related to the symptoms of SCD. In this review, we summarize the main imaging features and key findings regarding SCD related to AD, from local and regional data to connectivity-based imaging measures, with the aim of delineating a multimodal imaging signature of SCD due to AD. Additionally, the interaction of SCD with other risk factors for dementia due to AD, such as age and the Apolipoprotein E (ApoE) ɛ4 status, has also been described. Finally, the possible explanations for the inconsistent and heterogeneous neuroimaging findings observed in individuals with SCD are discussed, along with future directions. Overall, the literature reveals a preferential vulnerability of AD signature regions in SCD in the context of AD, supporting the notion that individuals with SCD share a similar pattern of brain alterations with patients with mild cognitive impairment (MCI) and dementia due to AD. We conclude that these neuroimaging techniques, particularly multimodal neuroimaging techniques, have great potential for identifying the underlying pathological alterations associated with SCD. More longitudinal studies with larger sample sizes combined with more advanced imaging modeling approaches such as artificial intelligence are still warranted to establish their clinical utility.

【 授权许可】

CC BY